The Big Cure for 2013 - Research Report on Biogen Idec Inc. and Keryx Biopharmaceuticals Inc.

Investors and patients are almost free from malaise after Biogen and Keryx announced good news that improved the outlook for the biopharmaceutical industry this year

Jan 23, 2013, 08:00 ET from National Traders Association

NEW YORK, January 23, 2013 /PRNewswire/ --

Biogen Idec Inc. (NASDAQ: BIIB) [Full Research Report][1] and Keryx Biopharmaceuticals Inc. (NASDAQ: KERX) [Free Research Report][2] both announced that marketing approvals are underway for their respective treatments, recombinant factor IX Fc fusion protein (rFIXFC) and Zerenex. Biogen's rFIXFC is the first product candidate in a new class of long-lasting clotting factor therapy for the treatment of hemophilia B. Keryx' Zerenex (ferric citrate) is an oral, iron-based compound for the treatment of kidney disease.

After separate disappointing news from Biogen and Keryx regarding the failure of their previous drug treatments for ALS and colorectal cancer, their good news this year are expected to push their sales and trading volumes to record-highs. Analysts are bullish that both companies can rake in significant revenues to brighten the shine of the lackluster biopharmaceutical industry. The probability of success is still not solid for Biogen or Keryx, but the positive outlook towards sales forecasts and stock advances for each company remains strong. Until the FDA green lights the marketing of both drugs can everyone be certain of a new reason to celebrate.

The huge factor which clouds the issue of size is the bull inflection which analysts and investors stood by during the toughest of times. Despite the huge risk when it comes to research and development, neither Biogen nor Keryx is at risk of suffering a tragic downfall. For instance, the risk of Keryx in going bankrupt is surprisingly close to none compared to its risk of getting disappointing results from phase 3 trials. It seems too hard to believe, but the development stage company actually gets royalty payments from its Japanese partner, JT Torii, every time it climbs a notch up the ladder. This is a good way for the company to cope with its run rate.

The success of Biogen and Keryx are yet to be solidified, but the signs are looking good. Most US investors tend to overlook the biopharmaceutical industry, and now is the right time to get their attention. Investing on companies like Biogen and Keryx during this time is may be foolproof. Biogen is one of the industry's best performers while Keryx is on the rise to compete with big names without too much risk through creating profitable partnerships.

Reference Links:

[1] The Full Research Report on Biogen Idec Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []

[2] The Free Research Report on Keryx Biopharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []

Consider National Traders Association

Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop -- long before they become the next top news on major financial networks.

Contact: Demi Lapierre Email: Main: +1-(702)-212-4493

SOURCE National Traders Association